ArticleTherapeutic advances in hematology2025
Real-world experience with tisagenlecleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma in Korea.
Dong Hyun Kim et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.